摘要
目的探讨连续2次单倍型异基因移植治疗重型再生障碍性贫血(severe aplastic anemia,SAA)失败后,更换单倍型供者行第3次移植治疗的可能性和安全性。方法 1例SAA患儿,以其父亲作为单倍型供者,于第1次单倍型外周血干细胞移植及第2次骨髓移植失败后,选择患儿母亲为单倍型供者进行第3次骨髓及外周血干细胞联合移植,其预处理方案采用Flu+CTX+ATG方案。结果第3次单倍型移植成功植入,植入证据检测为100%完全供者造血,患儿造血功能恢复正常,未发生移植物抗宿主病等严重并发症,随访至2015年1月仍存活。结论移植植入失败后行第3次单倍型异基因造血干细胞移植治疗SAA仍是安全有效的挽救治疗措施。
Objective To discuss the possibility and safety of the third-time haplotype transplantation to treat severe aplastic anemia after the failure of twice consecutive haplotype allogeneie hematopoietic stem cell transplantation and bone marrow transplantation. Methods One child with severe aplastic anemia underwent the third-time bone marrow combined with peripheral blood stem cell transplantation with the haplotype donor of his mother and the pretreatment scheme was Flu＋CTX＋ATG after the failure of haplotype peripheral blood stem cell transplantation and the failure of bone marrow transplantation with donor of his father. Results The third-time haplotype transplantation was successful, and the implantation evidence showed 100% complete donor hematopoiesis. The hematopoietic function recovered normally with no serious complications such as graft versus host disease. The patient was alive till the follow-up survey in January, 2015. Conclusion The third-time transplantation by haplotype ailogeneic hematopoietic stem cell is still effective and safe for severe aplastic anemia after implantation failure.
出处
《中华实用诊断与治疗杂志》
2015年第8期769-772,共4页
Journal of Chinese Practical Diagnosis and Therapy
基金
国家自然科学基金(31200686)
北京市首都临床特色课题(Z151100004015218)
关键词
重型再生障碍性贫血
单倍型
异基因造血干细胞移植
移植
Severe aplastic anemia
haplotype
allogeneic hematopoietic stem cell transplantations transplantation
